In Nov 2024, with @IFP and @RenPhil21, we realized that slow and inefficient trials were a key barrier to medical progress & launched the "Clinical Trial Abundance Initiative" -- a key theme we highlighted was FDA transparency & publishing CRL letters via @stuartbuck1's memo.
Dr. Martin Makary
Dr. Martin Makary10. juli, 21:05
Today, we're delivering on our promise of radical transparency. The FDA just published 200+ complete response letters—the actual decision letters we send to drug companies when applications need more work. No more guessing games. Developers, investors, and patients deserve to see how we make decisions.
16,06K